KALA BIO, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
KALA BIO, INC. (KALA) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $365.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2025-03-31
- KALA BIO, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2023-12-31 was $0.00.
- KALA BIO, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2023-09-30 was $0.00.
- KALA BIO, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2023-06-30 was $0.00.
- KALA BIO, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2023-03-31 was $365.00K, a 95.40% decline year-over-year.
- KALA BIO, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2023 was $365.00K, a 95.40% decline from fiscal 2022.
- KALA BIO, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2022 was $7.93M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $365.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $365.00K 10-Q · filed 2023-11-13 | $365.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $365.00K 10-Q · filed 2023-08-04 | $365.00K derived: sum of 3 quarters · filed 2024-11-12 | $365.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-03-31 | $365.00K 10-Q · filed 2024-11-12 | $365.00K derived: sum of 2 quarters · filed 2024-11-12 | $365.00K derived: sum of 3 quarters · filed 2024-11-12 | $365.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | $7.93M 10-K · filed 2024-03-29 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $7.93M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $7.93M 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | $7.93M 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |